FATE-NK100

N/A

Report date: 2026/03/10 20:00:16

Base Information

Drug NameFATE-NK100
Drug Alias NameFATE-NK100
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cells stimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFate Therapeutics IncMasonic Cancer Center, University Of Minnesota
Active IndicationsN/A
Inactive IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 

Other Information

ATC CodeN/A
Related LinksN/A